Europe Cannabidiol (CBD) Market Size, Share & Trends Analysis Report By Source Type (Hemp, Marijuana), By Sales Type (B2B, B2C), By End-use (Medical, Personal Use), By Region, And Segment- Industry Analysis, Share, Growth, Regional Outlook and Forecasts,
Description
The europe cannabidiol (CBD) market size was estimated at USD 409.90 million in 2023 and is projected to hit around USD 4,101.43 million by 2033, growing at a CAGR of 25.9% during the forecast period from 2024 to 2033.
Key Takeaways:
The European CBD market is expected to record lucrative growth with a CAGR of 25.9% over the forecast period
In 2023, hemp dominated the market and generated 56.16% of the revenue.
In B2B end-use, pharmaceuticals accounted for the largest revenue share of 74.19% in 2023.
B2B segment dominated the market and accounted for the largest revenue share of 56.12% in 2023.
The hospital pharmacies sub-segment within B2C is predicted to see substantial growth in the future.
Market Overview
The Europe Cannabidiol (CBD) market is evolving rapidly, emerging as one of the most dynamic consumer health and wellness sectors on the continent. Driven by regulatory liberalization, heightened consumer awareness, and innovations in formulation and application, the market has entered a new phase of maturity and diversification. CBD, a non-psychoactive compound derived from cannabis plants, is increasingly recognized for its therapeutic benefits in areas such as chronic pain, anxiety, inflammation, sleep disorders, epilepsy, and skincare.
Europe, with its patchwork of regulatory frameworks and diverse consumer bases, presents both challenges and opportunities for CBD businesses. Countries like the UK, Germany, and Switzerland are leading the way in terms of market size and progressive regulation, while other nations are slowly adapting their legislation to align with evolving EU standards. The European Food Safety Authority (EFSA) has played a crucial role in evaluating CBD as a novel food, providing a pathway for food and beverage products containing CBD to enter the legal market.
Companies across the value chain from cultivators and extractors to pharmaceutical firms, cosmetic brands, and nutraceutical startups are exploring CBD’s potential in functional wellness, personal care, and medical formulations. The growing inclusion of CBD in mainstream retail and pharmacy chains, coupled with an explosion in online sales, reflects its growing normalization in the European consumer mindset.
Major Trends in the Market
Normalization of CBD in Consumer Wellness: CBD is increasingly positioned alongside vitamins and adaptogens in wellness aisles and e-commerce platforms.
Pharmaceutical Expansion and Medical Research: Growing clinical trials and regulatory approvals are helping reposition CBD as a medically viable therapeutic.
Shift Toward Hemp-Derived CBD: Legal clarity and EU agricultural policies are favoring hemp as the preferred source for compliant CBD production.
Rise of B2C E-commerce Channels: Direct-to-consumer (DTC) brands are dominating with subscription models, influencer marketing, and personalized wellness solutions.
Product Innovation in Edibles and Beverages: Companies are launching CBD-infused gummies, sparkling waters, protein bars, and tinctures with enhanced bioavailability.
Focus on Sustainability and Organic Certification: Consumers are demanding transparency in sourcing and production, driving organic hemp farming and clean label CBD products.
Market Consolidation and Cross-Sector Partnerships: Traditional pharma, FMCG, and cosmetics players are entering the CBD space through acquisitions and joint ventures.
Europe Cannabidiol (CBD) Market Report Scope
Report Attribute
Details
Market Size in 2024
USD 516.06 million
Market Size by 2033
USD 4,101.43 million
Growth Rate From 2024 to 2033
CAGR of 25.9%
Base Year
2023
Forecast Period
2024 to 2033
Segments Covered
Source type, sales type, end-use, country
Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)
Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled
Jazz Pharmaceuticals; Canopy Growth Corporation; Tilray; Aurora Cannabis; Maricann, Inc.; Organigram Holding, Inc.; Isodiol International, Inc.; Medical Marijuana, Inc.; Elixinol; NuLeaf Naturals, LLC; Cannoid, LLC; CV Sceiences, Inc.; CHARLOTTE’S WEB.
Key Market Driver: Expanding Applications in Wellness and Pharmaceuticals
One of the most influential drivers of the Europe CBD market is the broadening scope of application across both wellness and pharmaceutical domains. Initially introduced through oils and tinctures for general well-being, CBD products are now found in food and beverage aisles, skincare shelves, fitness recovery kits, and even prescription counters.
For example, GW Pharmaceuticals’ Epidiolex, a CBD-based drug approved by both the U.S. FDA and European Medicines Agency (EMA) for epilepsy, has legitimized the medical use of cannabidiol. Simultaneously, wellness-focused consumers are turning to CBD to manage anxiety, muscle soreness, and insomnia especially in the wake of the COVID-19 pandemic which heightened interest in mental and immune health.
The dual utility of CBD backed by scientific research and consumer testimonials has created a robust demand curve that appeals to medical professionals, alternative health seekers, and mainstream consumers alike.
Key Market Restraint: Fragmented Regulatory Landscape
Despite growing momentum, a significant restraint in the European CBD market is the lack of regulatory uniformity across member states, which complicates market entry and scale for businesses. While the European Union classifies CBD as a novel food, each country has discretion in how to implement and enforce this policy.
For example, France banned CBD flowers, while Italy and Germany allow them under certain conditions. The UK, post-Brexit, introduced its own “CBD Novel Food List,” creating further compliance hurdles for exporters and manufacturers. These disparities affect everything from packaging and marketing to dosage limits and point-of-sale legality.
For companies operating across multiple countries, this means navigating a maze of licensing, labelling, testing, and enforcement variations raising operational costs and legal risks, especially for startups and SMEs.
Key Market Opportunity: Rise of Functional Foods and Beverages
A major opportunity lies in the intersection of CBD with the functional food and beverage market, which is expected to experience exponential growth over the next decade. As health-conscious consumers look for ways to manage stress, inflammation, and digestion through diet, CBD-infused consumables offer a compelling solution.
Innovations include CBD-infused herbal teas, sparkling waters, chocolates, granola bars, and non-alcoholic beverages, marketed as part of a healthy daily ritual. In Germany and the UK, retailers are already placing CBD beverages alongside natural health products, while in the Netherlands and Switzerland, local bars and cafés serve CBD-enhanced cocktails and lattes.
This convergence with established consumer behaviors offers a powerful scalability path for CBD companies, especially when paired with other functional ingredients like turmeric, magnesium, melatonin, and probiotics.
Segments Insights:
By Source Type
Hemp-derived CBD dominates the European market due to its favorable regulatory status, non-psychoactive profile, and agricultural incentives under the EU’s Common Agricultural Policy (CAP). Since hemp contains less than 0.2% THC (tetrahydrocannabinol), it meets the legal thresholds in most countries, making it the go-to source for CBD manufacturers. Hemp cultivation is supported in countries like France, Poland, and the Netherlands, leading to a stable and scalable supply chain.
Marijuana-derived CBD is growing, particularly in the medical segment where higher THC concentrations are permitted under prescription use. Countries such as Germany and the Czech Republic allow marijuana-derived cannabinoids for specific indications, but these products are tightly regulated, limiting their commercial reach in B2C markets. However, with ongoing trials and pilot programs, this segment may see expansion in the pharmaceutical and therapeutic sectors.
By Sales Type
B2C channels dominate the CBD market, especially through online and retail stores targeting wellness and personal care consumers. Online platforms have become a critical distribution point, enabling brands to directly engage customers with educational content, reviews, and subscription offers. Retail pharmacies and wellness boutiques also contribute significantly, offering CBD oils, skincare, and supplements alongside traditional products.
B2B sales are the fastest-growing, driven by partnerships between CBD producers and end-use industries such as pharmaceuticals, cosmetics, nutraceuticals, and food & beverage manufacturers. Ingredient-level sales of CBD isolates and full-spectrum extracts are enabling mass-market product formulation, especially in personal care and functional food brands seeking differentiation through plant-based health claims.
By End-use
Medical applications dominate, including treatment for chronic pain, mental health conditions, and neurological disorders. CBD's anti-inflammatory and neuroprotective effects have led to increased prescription and clinical use, particularly in Germany, where over 100,000 patients are estimated to use CBD therapeutically. Clinical trials continue to evaluate its impact on epilepsy, cancer-related pain, and PTSD, further reinforcing its legitimacy in medical use.
Wellness is the fastest-growing segment, especially in personal care, food & beverages, and nutraceuticals. Consumers are embracing CBD for its calming effects, anti-aging potential, and ability to support holistic health. Beauty brands across France and the UK have launched full CBD skincare lines, while Dutch bakeries, cafés, and health bars include CBD in daily menus. As demand for non-invasive, preventive care grows, wellness use of CBD is expected to outpace medical and pharmaceutical categories.
Country-Level Analysis: United Kingdom, Germany, Netherlands, Switzerland, Italy, France, Poland, Czech Republic, Croatia
United Kingdom
The UK is a key CBD market leader, having implemented a structured novel food application process post-Brexit. As of 2025, over 900 CBD products were awaiting approval from the Food Standards Agency (FSA), giving the market a clearer path than most EU countries. British consumers are also more accepting of CBD, especially in the wellness and beauty sectors. Domestic startups like Cannaray and CBDfx UK are driving innovation in branding and distribution.
Germany
Germany has the most advanced medical CBD infrastructure in Europe. The legal framework for cannabis-based medicines allows pharmacies to dispense CBD under prescription for chronic illnesses. Reimbursement policies and a well-organized health insurance system further support market stability. Additionally, Germany is likely to drive legislative reform for broader CBD commercialization, especially in light of ongoing adult-use cannabis legalization discussions.
Recent Developments
April 2025 – Canopy Growth launched a new line of CBD beverages in the UK in partnership with BioSteel, targeting sports and recovery markets.
March 2025 – Aurora Europe GmbH received approval to supply pharmaceutical-grade CBD oil to German pharmacies for epilepsy and palliative care use.
February 2025 – HemPoland (a subsidiary of The Green Organic Dutchman) expanded its CBD production facility in Poland to increase B2B supply capacity.
January 2025 – Cibdol, a Swiss CBD brand, introduced its first AI-enabled online diagnostic tool to help customers select CBD products based on health goals.
December 2024 – KannaSwiss collaborated with a French cosmetic company to co-launch a premium CBD-infused skincare line for European markets.
Key Europe CBD Companies:
The following are the leading companies in the Europe cannabidiol market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these Europe cannabidiol companies are analyzed to map the supply network.
Jazz Pharmaceuticals
Canopy Growth Corporation
Tilray
Aurora Cannabis
Maricann, Inc.
Organigram Holding, Inc.
Isodiol International, Inc.
Medical Marijuana, Inc.
Elixinol
NuLeaf Naturals, LLC
Cannoid, LLC
CV Sceiences, Inc.
CHARLOTTE’S WEB.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe Cannabidiol (CBD) market.
By Source Type
Hemp
Marijuana
By Sales Type
B2B
By End-use
Pharmaceuticals
Wellness
Food & Beverages
Personal Care & Cosmetics
Nutraceuticals
Others
B2C
By Sales Channel
Hospital Pharmacies
Online
Retail Stores
By End-use
Medical
Chronic Pain
Mental Disorders
Cancer
Others
Personal Use
By End-use
Medical
Chronic Pain
Mental Disorders
Cancer
Others
Personal Use
Pharmaceuticals
Wellness
Food & Beverages
Personal Care & Cosmetics
Nutraceuticals
Others
By Regional
Europe
UK
Germany
Netherlands
Switzerland
Italy
France
Poland
Czech Republic
Croatia
Key Takeaways:
The European CBD market is expected to record lucrative growth with a CAGR of 25.9% over the forecast period
In 2023, hemp dominated the market and generated 56.16% of the revenue.
In B2B end-use, pharmaceuticals accounted for the largest revenue share of 74.19% in 2023.
B2B segment dominated the market and accounted for the largest revenue share of 56.12% in 2023.
The hospital pharmacies sub-segment within B2C is predicted to see substantial growth in the future.
Market Overview
The Europe Cannabidiol (CBD) market is evolving rapidly, emerging as one of the most dynamic consumer health and wellness sectors on the continent. Driven by regulatory liberalization, heightened consumer awareness, and innovations in formulation and application, the market has entered a new phase of maturity and diversification. CBD, a non-psychoactive compound derived from cannabis plants, is increasingly recognized for its therapeutic benefits in areas such as chronic pain, anxiety, inflammation, sleep disorders, epilepsy, and skincare.
Europe, with its patchwork of regulatory frameworks and diverse consumer bases, presents both challenges and opportunities for CBD businesses. Countries like the UK, Germany, and Switzerland are leading the way in terms of market size and progressive regulation, while other nations are slowly adapting their legislation to align with evolving EU standards. The European Food Safety Authority (EFSA) has played a crucial role in evaluating CBD as a novel food, providing a pathway for food and beverage products containing CBD to enter the legal market.
Companies across the value chain from cultivators and extractors to pharmaceutical firms, cosmetic brands, and nutraceutical startups are exploring CBD’s potential in functional wellness, personal care, and medical formulations. The growing inclusion of CBD in mainstream retail and pharmacy chains, coupled with an explosion in online sales, reflects its growing normalization in the European consumer mindset.
Major Trends in the Market
Normalization of CBD in Consumer Wellness: CBD is increasingly positioned alongside vitamins and adaptogens in wellness aisles and e-commerce platforms.
Pharmaceutical Expansion and Medical Research: Growing clinical trials and regulatory approvals are helping reposition CBD as a medically viable therapeutic.
Shift Toward Hemp-Derived CBD: Legal clarity and EU agricultural policies are favoring hemp as the preferred source for compliant CBD production.
Rise of B2C E-commerce Channels: Direct-to-consumer (DTC) brands are dominating with subscription models, influencer marketing, and personalized wellness solutions.
Product Innovation in Edibles and Beverages: Companies are launching CBD-infused gummies, sparkling waters, protein bars, and tinctures with enhanced bioavailability.
Focus on Sustainability and Organic Certification: Consumers are demanding transparency in sourcing and production, driving organic hemp farming and clean label CBD products.
Market Consolidation and Cross-Sector Partnerships: Traditional pharma, FMCG, and cosmetics players are entering the CBD space through acquisitions and joint ventures.
Europe Cannabidiol (CBD) Market Report Scope
Report Attribute
Details
Market Size in 2024
USD 516.06 million
Market Size by 2033
USD 4,101.43 million
Growth Rate From 2024 to 2033
CAGR of 25.9%
Base Year
2023
Forecast Period
2024 to 2033
Segments Covered
Source type, sales type, end-use, country
Market Analysis (Terms Used)
Value (US$ Million/Billion) or (Volume/Units)
Report Coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled
Jazz Pharmaceuticals; Canopy Growth Corporation; Tilray; Aurora Cannabis; Maricann, Inc.; Organigram Holding, Inc.; Isodiol International, Inc.; Medical Marijuana, Inc.; Elixinol; NuLeaf Naturals, LLC; Cannoid, LLC; CV Sceiences, Inc.; CHARLOTTE’S WEB.
Key Market Driver: Expanding Applications in Wellness and Pharmaceuticals
One of the most influential drivers of the Europe CBD market is the broadening scope of application across both wellness and pharmaceutical domains. Initially introduced through oils and tinctures for general well-being, CBD products are now found in food and beverage aisles, skincare shelves, fitness recovery kits, and even prescription counters.
For example, GW Pharmaceuticals’ Epidiolex, a CBD-based drug approved by both the U.S. FDA and European Medicines Agency (EMA) for epilepsy, has legitimized the medical use of cannabidiol. Simultaneously, wellness-focused consumers are turning to CBD to manage anxiety, muscle soreness, and insomnia especially in the wake of the COVID-19 pandemic which heightened interest in mental and immune health.
The dual utility of CBD backed by scientific research and consumer testimonials has created a robust demand curve that appeals to medical professionals, alternative health seekers, and mainstream consumers alike.
Key Market Restraint: Fragmented Regulatory Landscape
Despite growing momentum, a significant restraint in the European CBD market is the lack of regulatory uniformity across member states, which complicates market entry and scale for businesses. While the European Union classifies CBD as a novel food, each country has discretion in how to implement and enforce this policy.
For example, France banned CBD flowers, while Italy and Germany allow them under certain conditions. The UK, post-Brexit, introduced its own “CBD Novel Food List,” creating further compliance hurdles for exporters and manufacturers. These disparities affect everything from packaging and marketing to dosage limits and point-of-sale legality.
For companies operating across multiple countries, this means navigating a maze of licensing, labelling, testing, and enforcement variations raising operational costs and legal risks, especially for startups and SMEs.
Key Market Opportunity: Rise of Functional Foods and Beverages
A major opportunity lies in the intersection of CBD with the functional food and beverage market, which is expected to experience exponential growth over the next decade. As health-conscious consumers look for ways to manage stress, inflammation, and digestion through diet, CBD-infused consumables offer a compelling solution.
Innovations include CBD-infused herbal teas, sparkling waters, chocolates, granola bars, and non-alcoholic beverages, marketed as part of a healthy daily ritual. In Germany and the UK, retailers are already placing CBD beverages alongside natural health products, while in the Netherlands and Switzerland, local bars and cafés serve CBD-enhanced cocktails and lattes.
This convergence with established consumer behaviors offers a powerful scalability path for CBD companies, especially when paired with other functional ingredients like turmeric, magnesium, melatonin, and probiotics.
Segments Insights:
By Source Type
Hemp-derived CBD dominates the European market due to its favorable regulatory status, non-psychoactive profile, and agricultural incentives under the EU’s Common Agricultural Policy (CAP). Since hemp contains less than 0.2% THC (tetrahydrocannabinol), it meets the legal thresholds in most countries, making it the go-to source for CBD manufacturers. Hemp cultivation is supported in countries like France, Poland, and the Netherlands, leading to a stable and scalable supply chain.
Marijuana-derived CBD is growing, particularly in the medical segment where higher THC concentrations are permitted under prescription use. Countries such as Germany and the Czech Republic allow marijuana-derived cannabinoids for specific indications, but these products are tightly regulated, limiting their commercial reach in B2C markets. However, with ongoing trials and pilot programs, this segment may see expansion in the pharmaceutical and therapeutic sectors.
By Sales Type
B2C channels dominate the CBD market, especially through online and retail stores targeting wellness and personal care consumers. Online platforms have become a critical distribution point, enabling brands to directly engage customers with educational content, reviews, and subscription offers. Retail pharmacies and wellness boutiques also contribute significantly, offering CBD oils, skincare, and supplements alongside traditional products.
B2B sales are the fastest-growing, driven by partnerships between CBD producers and end-use industries such as pharmaceuticals, cosmetics, nutraceuticals, and food & beverage manufacturers. Ingredient-level sales of CBD isolates and full-spectrum extracts are enabling mass-market product formulation, especially in personal care and functional food brands seeking differentiation through plant-based health claims.
By End-use
Medical applications dominate, including treatment for chronic pain, mental health conditions, and neurological disorders. CBD's anti-inflammatory and neuroprotective effects have led to increased prescription and clinical use, particularly in Germany, where over 100,000 patients are estimated to use CBD therapeutically. Clinical trials continue to evaluate its impact on epilepsy, cancer-related pain, and PTSD, further reinforcing its legitimacy in medical use.
Wellness is the fastest-growing segment, especially in personal care, food & beverages, and nutraceuticals. Consumers are embracing CBD for its calming effects, anti-aging potential, and ability to support holistic health. Beauty brands across France and the UK have launched full CBD skincare lines, while Dutch bakeries, cafés, and health bars include CBD in daily menus. As demand for non-invasive, preventive care grows, wellness use of CBD is expected to outpace medical and pharmaceutical categories.
Country-Level Analysis: United Kingdom, Germany, Netherlands, Switzerland, Italy, France, Poland, Czech Republic, Croatia
United Kingdom
The UK is a key CBD market leader, having implemented a structured novel food application process post-Brexit. As of 2025, over 900 CBD products were awaiting approval from the Food Standards Agency (FSA), giving the market a clearer path than most EU countries. British consumers are also more accepting of CBD, especially in the wellness and beauty sectors. Domestic startups like Cannaray and CBDfx UK are driving innovation in branding and distribution.
Germany
Germany has the most advanced medical CBD infrastructure in Europe. The legal framework for cannabis-based medicines allows pharmacies to dispense CBD under prescription for chronic illnesses. Reimbursement policies and a well-organized health insurance system further support market stability. Additionally, Germany is likely to drive legislative reform for broader CBD commercialization, especially in light of ongoing adult-use cannabis legalization discussions.
Recent Developments
April 2025 – Canopy Growth launched a new line of CBD beverages in the UK in partnership with BioSteel, targeting sports and recovery markets.
March 2025 – Aurora Europe GmbH received approval to supply pharmaceutical-grade CBD oil to German pharmacies for epilepsy and palliative care use.
February 2025 – HemPoland (a subsidiary of The Green Organic Dutchman) expanded its CBD production facility in Poland to increase B2B supply capacity.
January 2025 – Cibdol, a Swiss CBD brand, introduced its first AI-enabled online diagnostic tool to help customers select CBD products based on health goals.
December 2024 – KannaSwiss collaborated with a French cosmetic company to co-launch a premium CBD-infused skincare line for European markets.
Key Europe CBD Companies:
The following are the leading companies in the Europe cannabidiol market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these Europe cannabidiol companies are analyzed to map the supply network.
Jazz Pharmaceuticals
Canopy Growth Corporation
Tilray
Aurora Cannabis
Maricann, Inc.
Organigram Holding, Inc.
Isodiol International, Inc.
Medical Marijuana, Inc.
Elixinol
NuLeaf Naturals, LLC
Cannoid, LLC
CV Sceiences, Inc.
CHARLOTTE’S WEB.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe Cannabidiol (CBD) market.
By Source Type
Hemp
Marijuana
By Sales Type
B2B
By End-use
Pharmaceuticals
Wellness
Food & Beverages
Personal Care & Cosmetics
Nutraceuticals
Others
B2C
By Sales Channel
Hospital Pharmacies
Online
Retail Stores
By End-use
Medical
Chronic Pain
Mental Disorders
Cancer
Others
Personal Use
By End-use
Medical
Chronic Pain
Mental Disorders
Cancer
Others
Personal Use
Pharmaceuticals
Wellness
Food & Beverages
Personal Care & Cosmetics
Nutraceuticals
Others
By Regional
Europe
UK
Germany
Netherlands
Switzerland
Italy
France
Poland
Czech Republic
Croatia
Table of Contents
721 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Source Type
- 1.2.2. Sales Type
- 1.2.3. End-use
- 1.2.4. Country scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. Nova one advisors internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in Europe
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Source type outlook
- 2.2.2. Sales type outlook2
- 2.2.3. End-use outlook
- 2.2.4. Country outlook
- 2.3. Competitive Insights
- Chapter 3. Europe Cannabidiol Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Growing legalization of CBD-based products
- 3.2.1.2. Increasing preference for cannabis oils and tinctures
- 3.2.1.3. Growing adoption of CBD-based products for treating various medical conditions
- 3.2.1.4. Rise in number of retailers selling CBD-based products
- 3.2.2. Market restraint analysis
- 3.2.2.1. Stringent government regulations3
- 3.2.2.2. High cost of CBD in leading markets3.3. Europe Cannabidiol Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s Five Forces3
- 3.3.2. PESTEL Analysis
- 3.4. COVID-19 Impact Analysis
- Chapter 4. Europe Cannabidiol Market:SourceType Estimates & Trend Analysis
- 4.1. Europe Cannabidiol Market:SourceType Dashboard
- 4.2. Europe Cannabidiol Market:SourceType Movement Analysis
- 4.3. Europe Cannabidiol Market Size & Forecasts and Trend Analyses, 2024 - 2033
- 4.4. Hemp4.4.1. Market estimates and forecasts, 2021 - 20334.
- 5. Marijuana
- 5.1. Market estimates and forecasts, 2021 - 2033
- Chapter 5. Europe Cannabidiol Market: Sales Type Estimates & Trend Analysis
- 5.1. Europe Cannabidiol Market: Sales Type Dashboard
- 5.2. Europe Cannabidiol Market: Sales Type Movement Analysis
- 5.3. Europe Cannabidiol Market Size & Forecasts and Trend Analyses, 2024 - 2033
- 5.4. Business to Business (B2B)
- 5.4.1. Market estimates and forecasts, 2021 - 2033
- 5.5. Business to Consumer (B2C)
- 5.5.1. Hospital Pharmacies
- 5.5.1.1. Market estimates and forecasts, 2021 - 2033
- 5.5.2. Online Stores
- 5.5.2.1. Market estimates and forecasts, 2021 - 2033
- 5.5.3. Retail Stores
- 5.5.3.1. Market estimates and forecasts, 2021 - 2033
- Chapter 6. Europe Cannabidiol Market: End-use Estimates & Trend Analysis
- 6.1. Europe Cannabidiol Market: End-use Dashboard6.2. Europe Cannabidiol Market: End-use Movement Analysis
- 6.3. Europe Cannabidiol Market Size & Forecasts and Trend Analyses, 2024 - 2033
- 6.4. Medical
- 6.4.1. Chronic Pain
- 6.4.1.1. Market estimates and forecasts, 2021 - 2033
- 6.4.2. Mental Disorders
- 6.4.2.1. Market estimates and forecasts, 2021 - 2033
- 6.4.3. Cancer6.4.3.1. Market estimates and forecasts, 2021 - 20336.4.4. Others
- 6.4.4.1. Market estimates and forecasts, 2021 - 2033
- 6.5. Personal Use
- 6.5.1. Market estimates and forecasts, 2021 - 2033
- 6.6. Pharmaceutical
- 6.6.1. Market estimates and forecasts, 2021 - 2033
- 6.7. Wellness
- 6.7.1. Food & Beverages
- 6.7.1.1. Market estimates and forecasts, 2021 - 2033
- 6.7.2. Personal care & Cosmetics
- 6.7.2.1. Market estimates and forecasts, 2021 - 2033
- 6.7.3. Nutraceutical
- 6.7.3.1. Market estimates and forecasts, 2021 - 2033
- 6.7.4. Others
- 6.7.4.1. Market estimates and forecasts, 2021 - 2033
- Chapter 7. Regional Estimates & Trend Analysis by Source Type, Sales Type, End-use
- 7.1. Europe Cannabidiol Market: Regional Dashboard
- 7.2. Europe Cannabidiol Market: Regional Movement Analysis
- 7.3. Europe Cannabidiol Market Size & Forecasts and Trend Analyses by Source Type, Sales Type, End-use, 2024 - 2033
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. UK market estimates and forecasts, 2021 - 2033
- 7.4.2. Germany
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario7.4.2.4. Germany market estimates and forecasts, 2021 - 2033
- 7.4.3. Netherlands
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. Netherlands market estimates and forecasts, 2021 - 2033
- 7.4.4. Switzerland
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework/ reimbursement structure
- 7.4.4.3. Competitive scenario
- 7.4.4.4. Switzeland market estimates and forecasts, 2021 - 2033
- 7.4.5. Italy
- 7.4.5.1. Key country dynamics
- 7.4.5.2. Regulatory framework/ reimbursement structur
- 7.4.5.3. Competitive scenari
- 7.4.5.4. Italy market estimates and forecasts, 2021 - 2033
- 7.4.6. France
- 7.4.6.1. Key country dynamics
- 7.4.6.2. Regulatory framework/ reimbursement structure7.4.6.3. Competitive scenario7.4.6.4. France market estimates and forecasts, 2021 - 2033
- 7.4.7. Poland
- 7.4.7.1. Key country dynamics
- 7.4.7.2. Regulatory framework/ reimbursement structure
- 7.4.7.3. Competitive scenario
- 7.4.7.4. Poland market estimates and forecasts, 2021 - 2033
- 7.4.8. Czech Republic
- 7.4.8.1. Key country dynamics
- 7.4.8.2. Regulatory framework/ reimbursement structure
- 7.4.8.3. Competitive scenario
- 7.4.8.4. Czech Republic market estimates and forecasts, 2021 - 2033
- 7.4.9. Croatia
- 7.4.9.1. Key country dynamics
- 7.4.9.2. Regulatory framework/ reimbursement structure
- 7.4.9.3. Competitive scenario
- 7.4.9.4. Croatia market estimates and forecasts, 2021 - 2033
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key customers
- 8.3.2. Key company market share analysis, 2023
- 8.3.3. Jazz Pharmaceuticals
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Product benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. Canopy Growth Corporation
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Tilray
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performanc
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Aurora Cannabis
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Maricann, Inc.
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Organigram Holding, Inc.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Isodiol International, Inc.
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Medical Marijuana, Inc.
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Elixinol
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. NuLeaf Naturals, LLC
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Cannoid, LLC
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Product benchmarking
- 8.3.13.4. Strategic initiatives
- 8.3.14. CV Sciences, Inc.
- 8.3.14.1. Company overview
- 8.3.14.2. Financial performance
- 8.3.14.3. Product benchmarking
- 8.3.14.4. Strategic initiatives
- 8.3.15. CHARLOTTE’S WEB.
- 8.3.15.1. Company overview
- 8.3.15.2. Financial performance
- 8.3.15.3. Product benchmarking
- 8.3.15.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
